MX2023000577A - Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. - Google Patents

Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.

Info

Publication number
MX2023000577A
MX2023000577A MX2023000577A MX2023000577A MX2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A
Authority
MX
Mexico
Prior art keywords
atr kinase
compound used
kinase inhibitor
pyrazolopyrimidine compound
compound
Prior art date
Application number
MX2023000577A
Other languages
English (en)
Inventor
Bin Liu
Jing Li
Yanping Zhao
Hongjun Wang
Cheung Ling Cheng
Weiting Zhong
Huifen Xu
Chuangchuang Huang
Weina Liu
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of MX2023000577A publication Critical patent/MX2023000577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulga un compuesto de fórmula general (I), el cual puede usarse para el tratamiento de enfermedades mediadas por ATR cinasa, por ejemplo, enfermedades proliferativas, tal como cáncer. Se divulgan además un método de preparación para el compuesto de la fórmula general (I), una composición farmacéutica, y el uso de la composición farmacéutica para el tratamiento de enfermedades mediadas por ATR cinasa. (ver formula I).
MX2023000577A 2020-07-13 2021-07-13 Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. MX2023000577A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010669088 2020-07-13
CN202011163505 2020-10-27
PCT/CN2021/105867 WO2022012484A1 (zh) 2020-07-13 2021-07-13 作为atr激酶抑制剂的吡唑并嘧啶化合物

Publications (1)

Publication Number Publication Date
MX2023000577A true MX2023000577A (es) 2023-03-23

Family

ID=79274460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000577A MX2023000577A (es) 2020-07-13 2021-07-13 Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.

Country Status (12)

Country Link
US (1) US20230271968A1 (es)
EP (1) EP4166556A4 (es)
JP (1) JP2023534676A (es)
KR (1) KR20230039675A (es)
CN (2) CN113929688B (es)
AU (1) AU2021310000A1 (es)
BR (1) BR112023000654A2 (es)
CA (1) CA3185963A1 (es)
IL (1) IL299804A (es)
MX (1) MX2023000577A (es)
TW (1) TW202202506A (es)
WO (1) WO2022012484A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117247386A (zh) * 2022-01-18 2023-12-19 江苏亚尧生物科技有限公司 新型吡唑并嘧啶化合物及其组合物、制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2723745A1 (en) * 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP6133291B2 (ja) * 2011-08-12 2017-05-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
ES2954572T3 (es) * 2018-09-07 2023-11-23 Merck Patent Gmbh Derivados de 5-morfolin-4-il-pirazolo[4,3-b]piridina
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用

Also Published As

Publication number Publication date
IL299804A (en) 2023-03-01
JP2023534676A (ja) 2023-08-10
CN113929688A (zh) 2022-01-14
KR20230039675A (ko) 2023-03-21
BR112023000654A2 (pt) 2023-04-25
CN113929688B (zh) 2024-05-10
US20230271968A1 (en) 2023-08-31
TW202202506A (zh) 2022-01-16
EP4166556A4 (en) 2024-06-26
AU2021310000A1 (en) 2023-03-02
CA3185963A1 (en) 2022-01-20
CN115943145A (zh) 2023-04-07
WO2022012484A1 (zh) 2022-01-20
EP4166556A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
GEP20166484B (en) Protein kinase inhibitors
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2009004699A (es) Compuestos de piridinona.
WO2017128917A8 (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
CR20220068A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.